ACTIVE

2006-2010                   Centocor A Multicenter, Observational Study of the Long-term Safety of Infliximab (REMICADE) in Subjects with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), C0168T70

2006-2011                   NIH Severe Asthma Research Program (SARP). This program is to determine whether sequence variants in genes that regulate inflammation, cellular responses, tissue injury and repair or response to a specific therapy are more frequently associated with severe asthma by genotyping single nucleotide polymorphisms (SNPs) in 25 candidate genes.

2008-2010                   AstraZeneca Symbicort, A 52 Week, Randomized, Double blind, Parallel-group, Multi-center, Phase IIIB Study Comparing the Long Term Safety of SYMBICORT pMDI 160/4.5 mg x 2 Actuations Twice Daily to Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily in Adult and Adolescent (≥12 years) African American Subjects with Asthma

2008-2010                   MedImmune A Phase 2A, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of a Single-dose Intravenous Administration of MEDI-528, a Humanized Anti-interleukin-9 Monoclonal Antibody, on Allergen-induced  interkeukin-9 levels in Bronchoalveolar Lavage Fluid in Adults with Atopic Asthma

2007-2010                   GlaxoSmithKline A Study to Validate Key Therapeutic Targets and Characterize Their Response to corticosteroids in Multiple Asthma Phenotypes RES 100767

2008-2009                   Q3662g, A Phase IIIb Muliticenter, Randomized, Double-blind, Placebo-controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma Who Are Inadequately Controlled with High-dose Inhaled Corticosteroids and Long Acting Beta-Agonists

2008-2009                   NIH An Efficacy and Safety Study of Reslizumab (CTx 55700) in the Treatment of Poorly Controlled Asthma in Subjects with Eosinophilic Airway Inflammation

2008-2009                   Novartis Q2335S, A 26 Week Treatment, Multicenter, Randomized, Double- blind, Double Dummy, Placebo-Controlled, Adaptive, Seamless, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Indacaterol (selected from 75, 150, 300 & 600 mg o.d.) in Patients with Chronic Obstructive Pulmonary Disease using Blinded Formoterol (12mg b.i.d.) and Open Label Tiotropium (18mg o.d.) as Active Controls

2007-2009                NIH Asthma Clinical Research Program (ACRN). Best adjustment strategy for asthma in the long term (BASALT)

2007-2009                   NIH Asthma Clinical Research Program (ACRN). Tiotropium Bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC)

2007-2009                   Boehringer Ingelheim BI1222.6 A Randomized, Double-blind, Placebo, Parallel Group Study to Assess the Efficacy (bronchodilation)  and Safety of 4 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (2mg, 5 mg, 10mg, 20mg) Delivered by Respimat Inhaler in Patients with Asthma

2004-2009                   An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma (EXCELS), Q2948g